| Lipid Composition for FAD-201 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.300 | 0.21 | 20 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 1.185 | 0.93 | 79 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.15 mg/vial | 100 |
| Lipid Composition for FAD-202 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.075 | 0.05 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 1.410 | 1.11 | 94 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAD-203 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.015 | 0.01 | 1 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 1.470 | 1.16 | 98 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
| Lipid Composition for FAD-204 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.150 | 0.10 | 10 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.885 | 0.70 | 59 |
| Cholesterol | 0.450 | 0.17 | 30 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 0.98 mg/vial | 100 |
| Lipid Composition for FAD-205 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.300 | 0.21 | 20 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 1.185 | 0.93 | 79 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAD-206 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.075 | 0.05 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 1.410 | 1.11 | 94 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
| Lipid Composition for FAD-207 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.015 | 0.01 | 1 |
| L-alpha-Phosphatidylcholine | 1.470 | 1.13 | 98 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAD-208 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) | 0.150 | 0.10 | 10 |
| L-alpha-Phosphatidylcholine | 0.885 | 0.68 | 59 |
| Cholesterol | 0.450 | 0.17 | 30 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 0.97 mg/vial | 100 |
